X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (633) 633
Publication (80) 80
Book Chapter (16) 16
Book Review (11) 11
Conference Proceeding (1) 1
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pml (426) 426
humans (406) 406
progressive multifocal leukoencephalopathy (406) 406
index medicus (292) 292
clinical neurology (215) 215
jc virus (206) 206
neurosciences (195) 195
natalizumab (187) 187
female (175) 175
male (174) 174
multiple sclerosis (169) 169
adult (149) 149
middle aged (143) 143
neurology (127) 127
virology (118) 118
immunology (115) 115
leukoencephalopathy, progressive multifocal - virology (112) 112
magnetic resonance imaging (91) 91
infection (84) 84
infectious diseases (84) 84
leukoencephalopathy, progressive multifocal - diagnosis (84) 84
leukoencephalopathy, progressive multifocal - pathology (83) 83
aids (82) 82
viruses (79) 79
leukoencephalopathy (73) 73
patient (73) 73
hiv (72) 72
disease (71) 71
leukoencephalopathy, progressive multifocal (71) 71
jc virus - genetics (70) 70
virus diseases (69) 69
jc virus - isolation & purification (68) 68
cerebrospinal-fluid (67) 67
leukoencephalopathy, progressive multifocal - chemically induced (64) 64
leukoencephalopathy, progressive multifocal - drug therapy (64) 64
risk factors (62) 62
article (61) 61
brain - pathology (61) 61
multiple-sclerosis (61) 61
multiple sclerosis - drug therapy (59) 59
jcv (58) 58
therapy (58) 58
aged (57) 57
brain (55) 55
leukoencephalopathy, progressive multifocal - immunology (55) 55
biomedicine (54) 54
health aspects (53) 53
diagnosis (51) 51
leukoencephalopathy, progressive multifocal - etiology (51) 51
risk (50) 50
leukoencephalopathy, progressive multifocal - complications (48) 48
jc virus - immunology (47) 47
polyomavirus (46) 46
patients (45) 45
dna (43) 43
reconstitution inflammatory syndrome (42) 42
treatment outcome (41) 41
natalizumab - adverse effects (40) 40
care and treatment (39) 39
multiple sclerosis, relapsing-remitting - drug therapy (38) 38
active antiretroviral therapy (36) 36
leukoencephalopathy, progressive multifocal - epidemiology (36) 36
retrospective studies (36) 36
virus (35) 35
animals (34) 34
antibodies, monoclonal, humanized - adverse effects (34) 34
lymphocytes (34) 34
brain - virology (33) 33
natalizumab - therapeutic use (33) 33
pathogenesis (33) 33
pathology (32) 32
research (32) 32
antibodies, monoclonal, humanized - therapeutic use (31) 31
drug therapy (31) 31
immunologic factors - adverse effects (30) 30
survival (30) 30
young adult (30) 30
antibodies (29) 29
hiv infections - complications (29) 29
pml risk (29) 29
risk stratification (29) 29
rituximab (29) 29
immunologic factors - therapeutic use (28) 28
immunosuppressive agents - adverse effects (28) 28
medicine & public health (28) 28
immune reconstitution inflammatory syndrome (27) 27
infections (27) 27
jc virus - pathogenicity (27) 27
jc virus-dna (27) 27
cidofovir (26) 26
immunosuppressive agents - therapeutic use (26) 26
jc virus - physiology (26) 26
monoclonal antibodies (26) 26
pml-iris (26) 26
polymerase chain reaction (26) 26
prevalence (26) 26
biopsy (25) 25
central nervous system (25) 25
deoxyribonucleic acid--dna (25) 25
dimethyl fumarate (25) 25
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (611) 611
German (20) 20
French (4) 4
Japanese (3) 3
Russian (3) 3
Polish (2) 2
Spanish (2) 2
Croatian (1) 1
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neurology, ISSN 0028-3878, 2009, Volume 73, Issue 19, pp. 1551 - 1558
Background: We sought to characterize the role of immunologic, virologic, and radiologic determinants of survival in patients with progressive multifocal... 
STEROIDS | ACTIVE ANTIRETROVIRAL THERAPY | JC VIRUS EPITOPE | FREQUENCY | PML-IRIS | CLINICAL-COURSE | PROLONGED SURVIVAL | ASSOCIATION | CYTOTOXIC T-LYMPHOCYTES | CLINICAL NEUROLOGY | HAART
Journal Article
Neurology, ISSN 0028-3878, 04/2018, Volume 90, Issue 20, pp. E1815 - E1821
OBJECTIVEWe describe the characteristics of the 15 patients with fingolimod-associated progressive multifocal leukoencephalopathy (PML) identified from the... 
DIAGNOSIS | RELAPSING MULTIPLE-SCLEROSIS | ORAL FINGOLIMOD | RISK STRATIFICATION | PML RISK | NATALIZUMAB | THERAPIES | PATIENT | CLINICAL NEUROLOGY | 142
Journal Article
Neurology, ISSN 0028-3878, 05/2019, Volume 92, Issue 19, pp. e2232 - e2239
OBJECTIVETo evaluate characteristics relevant to diagnosis of JC polyomavirus-associated progressive multifocal leukoencephalopathy (PML), and PML risk... 
PLASMA | PATTERN | RISK | PATIENT | SERUM | PML | CLINICAL NEUROLOGY | JC VIRUS-ANTIBODIES
Journal Article
Journal of NeuroVirology, ISSN 1355-0284, 2019, Volume 25, Issue 2, pp. 284 - 287
Therapy for progressive multifocal leukoencephalopathy (PML) remains challenging since there are no antiviral therapies available for JC virus. Immune... 
PD-1 inhibitor | JC virus | Nivolumab | PML | Progressive multifocal leukoencephalopathy | THERAPY | VIROLOGY | CANCER | NEUROSCIENCES
Journal Article
Nervenarzt, ISSN 0028-2804, 12/2016, Volume 87, Issue 12, pp. 1300 - 1304
Journal Article
2018, ISBN 9780444638496, Volume 152
Progressive multifocal leukoencephalopathy (PML) is a relatively common complication of HIV disease. In this chapter changes to the epidemiology are discussed... 
IRIS | maraviroc | HIV | JCV | PML | mirtazepine
Book Chapter
JAMA Neurology, ISSN 2168-6149, 08/2014, Volume 71, Issue 8, pp. 1030 - 1035
Journal Article
Joint Bone Spine, ISSN 1297-319X, 2017, Volume 84, Issue 6, pp. 671 - 675
Abstract Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system due to reactivation of the JC virus (JCV).... 
Internal Medicine | Rheumatology | Biotherapies | Rituximab | TNFα antagonists | Rheumatoid arthritis | Progressive multifocal leukoencephalopathy | SYSTEMIC-LUPUS-ERYTHEMATOSUS | RISK-FACTORS | INFLAMMATORY DISEASES | JC VIRUS-DNA | RHEUMATOLOGY | PML | PATHOGENESIS | BRAIN-TISSUE | POLYOMAVIRUS | THERAPY | leukoencephalopathy | Progressive multifocal | TNF alpha antagonists | ANTI-TNF-ALPHA | Severity of Illness Index | Prognosis | Risk Assessment | Humans | Natalizumab - adverse effects | Antibodies, Monoclonal - adverse effects | Male | Rare Diseases | Incidence | Rituximab - therapeutic use | Antibodies, Monoclonal - administration & dosage | Arthritis, Rheumatoid - drug therapy | HIV Infections - diagnosis | Natalizumab - therapeutic use | Leukoencephalopathy, Progressive Multifocal - etiology | Biological Products - adverse effects | Female | HIV Infections - drug therapy | Arthritis, Rheumatoid - diagnosis | Leukoencephalopathy, Progressive Multifocal - epidemiology | Leukoencephalopathy, Progressive Multifocal - physiopathology | Biological Products - therapeutic use | Rituximab - adverse effects | Multiple sclerosis | Biological products | Genomics | Arthritis | HIV (Viruses) | Risk factors | Rheumatoid factor | Immunotherapy | Leukoencephalopathy, Progressive multifocal | Monoclonal antibodies | Brain damage | Rankings | Drug therapy | Health aspects | HIV infection | Leukoencephalopathy
Journal Article
European Journal of Neurology, ISSN 1351-5101, 04/2019, Volume 26, Issue 4, pp. 566 - e41
John Cunningham virus (JCV) infection of the central nervous system causes progressive multifocal leukoencephalopathy (PML) in patients with systemic... 
JC virus | progressive multifocal leukoencephalopathy | ANTIBODY | RISK | GRANULE CELL NEURONOPATHY | NATALIZUMAB | JC VIRUS MENINGITIS |